These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 31847542)

  • 21. Vaginal Gene Expression During Treatment With Aromatase Inhibitors.
    Kallak TK; Baumgart J; Nilsson K; Åkerud H; Poromaa IS; Stavreus-Evers A
    Clin Breast Cancer; 2015 Dec; 15(6):527-535.e2. PubMed ID: 26283501
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CYP11A1 expression in bone is associated with aromatase inhibitor-related bone loss.
    Rodríguez-Sanz M; García-Giralt N; Prieto-Alhambra D; Servitja S; Balcells S; Pecorelli R; Díez-Pérez A; Grinberg D; Tusquets I; Nogués X
    J Mol Endocrinol; 2015 Aug; 55(1):69-79. PubMed ID: 26108486
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aromatase inhibitor-related musculoskeletal symptoms: is preventing osteoporosis the key to eliminating these symptoms?
    Muslimani AA; Spiro TP; Chaudhry AA; Taylor HC; Jaiyesimi I; Daw HA
    Clin Breast Cancer; 2009 Feb; 9(1):34-8. PubMed ID: 19299238
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor Therapy.
    Santa-Maria CA; Blackford A; Nguyen AT; Skaar TC; Philips S; Oesterreich S; Rae JM; Desta Z; Robarge J; Henry NL; Storniolo AM; Hayes DF; Blumenthal RS; Ouyang P; Post WS; Flockhart DA; Stearns V;
    Clin Cancer Res; 2016 Mar; 22(6):1395-402. PubMed ID: 26463708
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Androgens and musculoskeletal symptoms among breast cancer patients on aromatase inhibitor therapy.
    Gallicchio L; Macdonald R; Wood B; Rushovich E; Helzlsouer KJ
    Breast Cancer Res Treat; 2011 Nov; 130(2):569-77. PubMed ID: 21647676
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjuvant hormonal therapy in peri- and postmenopausal breast cancer.
    Ryan PD; Goss PE
    Oncologist; 2006; 11(7):718-31. PubMed ID: 16880231
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Further Evidence That OPG rs2073618 Is Associated With Increased Risk of Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors for Early Breast Cancer.
    Hertz DL; Smith KL; Zong Y; Gersch CL; Pesch AM; Lehman J; Blackford AL; Henry NL; Kidwell KM; Rae JM; Stearns V
    Front Genet; 2021; 12():662734. PubMed ID: 34211496
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patients.
    Gao Q; López-Knowles E; Cheang MCU; Morden J; Ribas R; Sidhu K; Evans D; Martins V; Dodson A; Skene A; Holcombe C; Mallon E; Evans A; Bliss JM; Robertson J; Smith I; Martin LA; Dowsett M;
    Breast Cancer Res; 2019 Dec; 22(1):2. PubMed ID: 31892336
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of aromatase inhibitors on bone health in breast cancer patients.
    Geisler J; Lønning PE
    J Steroid Biochem Mol Biol; 2010 Feb; 118(4-5):294-9. PubMed ID: 19833206
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular basis of aromatase inhibitor associated arthralgia: known and potential candidate genes and associated biomarkers.
    Borrie AE; Kim RB
    Expert Opin Drug Metab Toxicol; 2017 Feb; 13(2):149-156. PubMed ID: 27635473
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety of aromatase inhibitor therapy in breast cancer.
    Lintermans A; Neven P
    Expert Opin Drug Saf; 2015 Aug; 14(8):1201-11. PubMed ID: 26059833
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management of aromatase inhibitor induced musculoskeletal symptoms in postmenopausal early Breast cancer: A systematic review and meta-analysis.
    Roberts K; Rickett K; Greer R; Woodward N
    Crit Rev Oncol Hematol; 2017 Mar; 111():66-80. PubMed ID: 28259297
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized placebo-controlled pilot trial of omega 3 fatty acids for prevention of aromatase inhibitor-induced musculoskeletal pain.
    Lustberg MB; Orchard TS; Reinbolt R; Andridge R; Pan X; Belury M; Cole R; Logan A; Layman R; Ramaswamy B; Wesolowski R; Berger M; Patterson E; Loprinzi C; Shapiro CL; Yee L
    Breast Cancer Res Treat; 2018 Feb; 167(3):709-718. PubMed ID: 29101597
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
    Carpenter R
    Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Do all aromatase inhibitors have similar efficacy and safety?
    Şendur MA; Bilgin B; Hızal M; Özdemir NY; Akıncı MB; Dede DŞ; Yalçın B
    Future Oncol; 2017 Aug; 13(19):1673-1676. PubMed ID: 28831832
    [No Abstract]   [Full Text] [Related]  

  • 36. Changes in bone biomarker concentrations and musculoskeletal symptoms among breast cancer patients initiating aromatase inhibitor therapy and women without a history of cancer.
    Gallicchio L; MacDonald R; Wood B; Rushovich E; Fedarko NS; Helzlsouer KJ
    J Bone Miner Res; 2012 Sep; 27(9):1959-66. PubMed ID: 22508239
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Utilization of gynecologic services in women with breast cancer receiving hormonal therapy.
    Wright JD; Desai VB; Chen L; Burke WM; Tergas AI; Hou JY; Accordino M; Ananth CV; Neugut AI; Hershman DL
    Am J Obstet Gynecol; 2017 Jul; 217(1):59.e1-59.e12. PubMed ID: 28341383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aromatase inhibitors and musculoskeletal symptoms.
    Khanduri S; Dodwell DJ
    Breast; 2008 Feb; 17(1):76-9. PubMed ID: 17822901
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pre-menopausal breast cancer and aromatase inhibitors: Treating a new generation of women.
    Freedman OC; Verma S; Clemons MJ
    Breast Cancer Res Treat; 2006 Oct; 99(3):241-7. PubMed ID: 16752075
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II clinical trial of high-dose toremifene as primary hormone therapy in aromatase inhibitor-resistant breast cancer.
    Ogata H; Okamoto Y; Arima Y; Fukushima H; Takeyama H; Yamashita A; Kinoshita M; Suzuki N; Sawada T; Koshida Y; Matsui A; Tachibana A; Nakayama H; Oishi Y; Nogi H; Uchida K
    Gan To Kagaku Ryoho; 2013 Jun; 40(6):749-53. PubMed ID: 23863651
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.